pembrolizumab + SurVaxM

Pembrolizumab + SurVaxM is an investigational combination therapy being studied primarily for the treatment of recurrent glioblastoma. Pembrolizumab is a humanized immunoglobulin G4 (IgG4) monoclonal antibody that targets the programmed cell death 1 (PD-1) receptor, blocking its interaction with PD-L1 and PD-L2, thereby enhancing T-cell mediated immune responses against tumor cells. SurVaxM is a peptide-based cancer vaccine designed to stimulate both cellular and humoral immune responses against survivin, an intracellular inhibitor of apoptosis protein highly expressed in glioblastoma and many other cancers. The combination aims to leverage checkpoint inhibition with pembrolizumab alongside active immunization against survivin-expressing tumor cells by SurVaxM, potentially improving progression-free survival and overall survival in patients with recurrent glioblastoma[1][2][3][4][5].